<DOC>
	<DOCNO>NCT02482974</DOCNO>
	<brief_summary>This study aim determine safety efficacy conversion sirolimus everolimus maintenance treatment LT recipient . Patients monitor every 12 week switch treatment 48 week . The laboratory test include hematological , renal , hepatic , metabolic parameter perform visit . Twenty-four-hour urine creatinine clearance proteinuria determine 24-hour urine collection baseline week 48 .</brief_summary>
	<brief_title>Conversion From Sirolimus Everolimus Maintenance Treatment Liver Transplant Recipients</brief_title>
	<detailed_description>Everolimus ( EVL ) sirolimus ( SRL ) , antagonist mammalian target rapamycin , introduce solid organ transplantation either replace reduce dose potentially nephrotoxic calcineurin inhibitor . Although approve liver transplantation ( LT ) , SRL still use several LT center . After EVL approve FDA Ministry Health Turkey use LT recipient , SRL convert EVL institution . This study aim determine safety efficacy conversion SRL EVL maintenance treatment LT recipient . Patients switch SRL EVL monitor every 12 week switch treatment 48 week . Efficacy measure include observation term biopsy-proven acute/chronic rejection graft patient loss due rejection . Safety evaluation include discontinuation EVL analyse adverse event grade laboratory abnormality . Laboratory evaluation include hematological ( CBC ) , renal ( serum creatinine , estimate glomerular filtration rate [ eGFR ; Modification Diet Renal Disease ( MDRD ) Chronic Kidney Disease-Epidemiology Collaboration ( CKD-EPI ) ] , electrolytes ) , hepatic ( serum transaminase , alkaline phosphatase , Î³-glutamyl transferase , bilirubin , albumin ) , metabolic parameter ( fast glucose , cholesterol , triglyceride ) visit . Twenty-four-hour urine creatinine clearance proteinuria determine 24-hour urine collection baseline week 48 . For patient additional immunosuppressive treatment , medication also continue .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients older 18 year Liver transplant recipient switch sirolimus everolimus Patients refuse everolimus switch</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Safety</keyword>
</DOC>